| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Philippe Chanso. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Best practice & research. Clinical endocrinology & metabolism. 2022-10-24. PMID:36280567. |
treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. |
2022-10-24 |
2023-08-14 |
Not clear |
| Polly Kirsch, Jessica Kunadia, Shruti Shah, Nidhi Agrawa. Metabolic effects of prolactin and the role of dopamine agonists: A review. Frontiers in endocrinology. vol 13. 2022-10-17. PMID:36246929. |
furthermore, the effect of dopamine agonists on the metabolic profiles of patients with hyperprolactinemia are discussed as well. |
2022-10-17 |
2023-08-14 |
Not clear |
| Anahid Hamidianjahromi, Nicholas A Trito. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Reviews in endocrine & metabolic disorders. 2022-09-20. PMID:36125673. |
dopamine agonists (das) represent a mainstay of therapy for hyperprolactinemia and prolactinomas. |
2022-09-20 |
2023-08-14 |
Not clear |
| Matteo Lippi, Giuseppe Fanelli, Chiara Fabbri, Diana De Ronchi, Alessandro Serrett. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? International clinical psychopharmacology. 2022-07-11. PMID:35815937. |
previous evidence indicates the utility of low-dose partial dopamine agonist (pdas) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. |
2022-07-11 |
2023-08-14 |
Not clear |
| Md Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md Habibur Rahma. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus. Environmental science and pollution research international. 2022-04-29. PMID:35486279. |
dopamine agonists are usually used in neurological disorders like parkinson's disease (pd), restless leg syndrome, and hyperprolactinemia. |
2022-04-29 |
2023-08-13 |
Not clear |
| Hua Feng, Qiuxi Zhong, Huifang Zhou, Xiaoyue Jiang, Yinyin Din. The effects of combined bromocriptine and Bu-shen-zhu-yun decoction on serum hormones, anxiety, and pregnancy in hyperprolactinemic infertility patients. Annals of palliative medicine. vol 10. issue 12. 2022-01-12. PMID:35016475. |
hyperprolactinemia (hprl), a pathological phenomenon of excessive prl, can cause infertility in severe cases and is currently treated mainly with western drugs, such as bromocriptine, a dopamine agonist (da). |
2022-01-12 |
2023-08-13 |
Not clear |
| Tse-Yu Chen, Chung-Hsin Lee, Meng-Yin Yang, Chiung-Chyi Shen, Yin-Ping Yang, Yueh Chien, Yu-Fen Huang, Chih-Ming Lai, Wen-Yu Chen. Treatment of hyperprolactinemia: A single-institute experience. Journal of the Chinese Medical Association : JCMA. vol 84. issue 11. 2021-12-09. PMID:34261980. |
dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. |
2021-12-09 |
2023-08-13 |
Not clear |
| Wenyu Huang, Mark E Molitc. Prolactin and Other Pituitary Disorders in Kidney Disease. Seminars in nephrology. vol 41. issue 2. 2021-12-01. PMID:34140094. |
treatment of hyperprolactinemia should focus on improving bothersome galactorrhea or hypogonadism by using dopamine agonists and/or replacement of sex hormone(s). |
2021-12-01 |
2023-08-13 |
human |
| Lina You, Haidong Jian. Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS). Bioengineered. vol 12. issue 1. 2021-11-23. PMID:34592907. |
cabergoline is a specific dopamine d2 receptor agonist developed to treat parkinson's disease and hyperprolactinemia and is reported to exert promising anti-inflammatory properties. |
2021-11-23 |
2023-08-13 |
mouse |
| A T Mathews, C M Banks, J F Trott, R D Sainz, C Farmer, I I Pendergast, R C Hove. Metoclopramide induces preparturient, low-level hyperprolactinemia to increase milk production in primiparous sows. Domestic animal endocrinology. vol 74. 2021-11-19. PMID:32739764. |
we hypothesized that induction of late gestational hyperprolactinemia in primiparous sows by oral administration of the dopamine antagonist metoclopramide (met) would enhance mammary epithelial differentiation, milk yield, and piglet growth rate and that these effects would carry over into a subsequent lactation. |
2021-11-19 |
2023-08-13 |
Not clear |
| Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jian. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders. vol 21. issue 1. 2021-11-18. PMID:34774043. |
prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (das) are generally the first-line treatment for them. |
2021-11-18 |
2023-08-13 |
Not clear |
| Clemente García-Rizo, Javier Vázquez-Bourgon, Javier Labad, Víctor Ortiz García de la Foz, Marcos Gómez-Revuelta, María Juncal Ruiz, Benedicto Crespo-Facorr. Prolactin, metabolic and immune parameters in naïve subjects with a first episode of psychosis. Progress in neuro-psychopharmacology & biological psychiatry. vol 110. 2021-11-01. PMID:33891977. |
its regulation through dopamine receptors highlights its importance in psychiatry mostly because hyperprolactinemia is a common secondary side effect of dopamine antagonists. |
2021-11-01 |
2023-08-13 |
human |
| Olga Yu Fedorenko, Diana Z Paderina, Anton J M Loonen, Ivan V Pozhidaev, Anastasiia S Boiko, Elena G Kornetova, Nikolay A Bokhan, Bob Wilffert, Svetlana A Ivanov. Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. Human psychopharmacology. vol 35. issue 4. 2021-06-09. PMID:32383805. |
hyperprolactinemia (hprl), a common adverse effect of antipsychotics, is attributed to blockade of dopamine d2 receptors. |
2021-06-09 |
2023-08-13 |
Not clear |
| Alexandre González-Rodríguez, Javier Labad, Mary V Seema. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. Progress in neuro-psychopharmacology & biological psychiatry. vol 101. 2021-06-04. PMID:32243999. |
almost all antipsychotics lead to hyperprolactinemia by blocking dopamine d2 receptors in the anterior pituitary gland, which counteracts dopamine's inhibitory action on prolactin secretion. |
2021-06-04 |
2023-08-13 |
Not clear |
| Ying-Lin Huang, Miao Peng, Gang Zh. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. Medical hypotheses. vol 138. 2021-05-14. PMID:32035285. |
current treatments for antipsychotic-induced hyperprolactinemia exert their action mainly through the mechanism of enhancing the inhibitory effect of dopamine on prolactin secretion; however, patients have to endure the risk of psychotic relapse or exacerbation. |
2021-05-14 |
2023-08-13 |
Not clear |
| Tae Maeshima, Ryosuke Iijima, Machiko Watanabe, Satoru Yui, Fumio Itagak. Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments. Journal of pharmaceutical health care and sciences. vol 7. issue 1. 2021-04-05. PMID:33789764. |
since antipsychotics induce hyperprolactinemia via the dopamine d |
2021-04-05 |
2023-08-13 |
Not clear |
| Xiaoqian Huang, Liying Ren, Lianbing Hou, Hua Fan, Chengliang Wang, Chunxia Wang, Yuhao L. Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary. Journal of ethnopharmacology. vol 257. 2021-02-24. PMID:32294507. |
paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine d2 receptor and tgf-β1 signaling pathways in the hypothalamus and pituitary. |
2021-02-24 |
2023-08-13 |
rat |
| Felicitas Lopez-Vicchi, Sharon R Ladyman, Ana Maria Ornstein, Papillon Gustafson, Penelope Knowles, Guillermina Maria Luque, David R Grattan, Damasia Becu-Villalobo. Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 34. issue 3. 2021-01-25. PMID:31944423. |
to study the pathological effects of continuous hyperprolactinemia on food intake mechanisms we used female mice that lack dopamine d2 receptors in lactotropes (lacdrd2ko). |
2021-01-25 |
2023-08-13 |
mouse |
| Phronpan Chutpiboonwat, Kanchana Yenpinyosuk, Vitaya Sridama, Supaksorn Kunjan, Karuna Klaimukh, Thiti Snabboo. Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center. The Pan African medical journal. vol 36. 2020-12-24. PMID:32550971. |
all patients with macroprolactinemia were women, of which eight of them were initially diagnosed as idiopathic hyperprolactinemia and mistreated with dopamine agonist medications. |
2020-12-24 |
2023-08-13 |
Not clear |
| Amarnath Se. Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus? Medical hypotheses. vol 144. 2020-12-14. PMID:33254515. |
it has been reported that by controlled enhancement of blood prl level (within the physiological limit and in some cases a little elevated above the normal to induce mild hyperprolactinemia) using dopamine antagonists such immune-stimulatory advantage can led to survival of the patients in many critical conditions. |
2020-12-14 |
2023-08-13 |
Not clear |